🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
335

Quick answer

Takeda has 335 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. CUVITRU - Ig subcutaneous human 20%

    Takeda

    COPD Exacerbation Acute

    phase 2 mab active

    1 trial

  2. CX501

    Takeda

    EPIDERMOLYSIS BULLOSA

    phase 2 small molecule completed

    1 trial

  3. Cabozantinib

    Takeda

    Advanced Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  4. Cabozantinib

    Takeda

    Advanced Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  5. Celaderm (Frozen Cultured Epidermal Allograft)

    Takeda

    Leg Ulcer

    phase 2 other completed

    1 trial

  6. Clarithromycin

    Takeda

    Myeloma

    phase 2 small molecule active

    1 trial

  7. Colchicine, 0.6 mg PO BID

    Takeda

    Atrial Fibrillation

    phase 2 small molecule completed

    1 trial

  8. Cx611

    Takeda

    Bacterial Pneumonia

    phase 2 mab completed

    1 trial

  9. Cyclophosphamide

    Takeda

    B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

    phase 2 small molecule active

    1 trial

  10. Cyclophosphamide

    Takeda

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  11. DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC

    Takeda

    Erosive Esophagitis

    phase 2 small molecule active

    1 trial

  12. DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC

    Takeda

    Symptomatic nonerosive GERD in paediatric subjects aged 2 to 11 years

    phase 2 small molecule active

    1 trial

  13. DX-88 (ecallantide)

    Takeda

    Hereditary Angioedema (HAE)

    phase 2 small molecule completed

    1 trial

  14. Danavorexton

    Takeda

    Sleep Apnea

    phase 2 small molecule completed

    2 trials

  15. Daratumumab, Ixazomib, Dexamethasone

    Takeda

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  16. Dasatinib

    Takeda

    Acute Lymphoblastic Leukemia

    phase 2 small molecule terminated

    1 trial

  17. Dazostinag

    Takeda

    Solid Neoplasms

    phase 2 small molecule completed

    1 trial

  18. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux Disease (GERD)

    phase 2 small molecule active

    1 trial

  19. Dexlansoprazole

    Takeda

    Barrett's Esophagus

    phase 2 small molecule terminated

    1 trial

  20. Docetaxel

    Takeda

    Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  21. Elritercept

    Takeda

    Myelodysplastic Syndromes

    phase 2 small molecule active

    2 trials

  22. Elritercept

    Takeda

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  23. Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Ulcerative Colitis or Crohn's Disease

    phase 2 small molecule active

    1 trial

  24. Everolimus

    Takeda

    Clear-cell Metastatic Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  25. FST-100

    Takeda

    Acute Adenoviral Conjunctivitis

    phase 2 small molecule completed

    1 trial

  26. FST-100

    Takeda

    Acute Viral Conjunctivitis

    phase 2 small molecule completed

    1 trial

  27. FST-100 Ophthalmic Suspension

    Takeda

    Acute Adenoviral Conjunctivitis

    phase 2 small molecule terminated

    1 trial

  28. Fasiglifam

    Takeda

    Type 2 Diabetes Mellitus

    phase 2 small molecule terminated

    2 trials

  29. Febuxostat

    Takeda

    Renal Impairment

    phase 2 small molecule completed

    1 trial

  30. Febuxostat

    Takeda

    Joint Damage

    phase 2 small molecule completed

    1 trial

  31. Febuxostat

    Takeda

    Angina

    phase 2 small molecule terminated

    1 trial

  32. Febuxostat

    Takeda

    Hypertension

    phase 2 small molecule completed

    1 trial

  33. Febuxostat

    Takeda

    Hyperuricosuria

    phase 2 small molecule completed

    1 trial

  34. Fruquintinib Combined With Chemotherapy

    Takeda

    Metastatic Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial

  35. GA-GCB

    Takeda

    Gaucher Disease

    phase 2 small molecule completed

    1 trial

  36. GDX012

    Takeda

    Leukemia

    phase 2 small molecule terminated

    1 trial

  37. GI.1/GII.4 (15/15)

    Takeda

    Norovirus

    phase 2 mab completed

    1 trial

  38. HGT-1110

    Takeda

    Metachromatic Leukodystrophy (MLD)

    phase 2 mab completed

    1 trial

  39. HGT-1111

    Takeda

    Late Infantile Metachromatic Leukodystrophy

    phase 2 small molecule terminated

    1 trial

  40. HGT-1410

    Takeda

    Sanfilippo Syndrome

    phase 2 small molecule terminated

    1 trial

  41. HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN, SALINE, HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN

    Takeda

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  42. Hepatitis A Vaccine

    Takeda

    Healthy Volunteers

    phase 2 mab completed

    1 trial

  43. IXAZOMIB

    Takeda

    Follicular Lymphoma

    phase 2 small molecule completed

    1 trial

  44. Iclusig 30 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Ponatinib

    Takeda

    Chronic Phase Chronic Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  45. Idursulfase IT (1 mg)

    Takeda

    Hunter Syndrome

    phase 2 small molecule completed

    1 trial

  46. Ilaprazole

    Takeda

    Esophagitis

    phase 2 small molecule completed

    1 trial

  47. Immune Globulin Infusion (Human), 10% Solution

    Takeda

    Hematologic Malignancies

    phase 2 mab active

    1 trial

  48. Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

335 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.